AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 72 filers reported holding AMYLYX PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,901,477 | +2.8% | 267,694 | +21.1% | 0.06% | -10.9% |
| Q2 2023 | $4,769,839 | -26.6% | 221,133 | -0.2% | 0.06% | -28.9% |
| Q1 2023 | $6,501,685 | -32.5% | 221,598 | -15.0% | 0.09% | -40.0% |
| Q4 2022 | $9,627,359 | -29.8% | 260,551 | -67.4% | 0.15% | -3.2% |
| Q3 2022 | $13,720,795 | -25.0% | 799,533 | -15.9% | 0.16% | -57.2% |
| Q2 2022 | $18,299,000 | +53.9% | 950,129 | +2.7% | 0.36% | +153.1% |
| Q1 2022 | $11,891,000 | – | 925,353 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,756,050 | $35,415,000 | 3.44% |
| Boxer Capital, LLC | 2,200,000 | $28,270,000 | 1.45% |
| Alpha Wave Global, LP | 617,220 | $7,931,000 | 0.72% |
| Ikarian Capital, LLC | 396,654 | $5,097,000 | 0.67% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 768,603 | $9,877,000 | 0.58% |
| Ikarian Capital, LLC | 250,000 | $3,213,000 | 0.42% |
| 683 Capital Management, LLC | 677,714 | $7,685,000 | 0.41% |
| Perceptive Advisors | 1,474,107 | $18,942,000 | 0.38% |
| VIKING GLOBAL INVESTORS LP | 7,170,536 | $92,141,000 | 0.37% |
| Rock Springs Capital Management LP | 998,307 | $12,828,000 | 0.32% |